Induction and Maintaining Remission of Collagenous Colitis Clinical Trial
— SCCMSOfficial title:
Double-blind, Randomised, Placebo-controlled, Multi-centre Phase III Clinical Study on the Efficacy and Tolerability of Budesonide Capsules Versus Placebo for Maintenance of Remission in Patients With Collagenous Colitis
| Verified date | January 2016 |
| Source | Dr. Falk Pharma GmbH |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Sweden: Medical Products Agency |
| Study type | Interventional |
This study aims to demonstrate the superiority of budesonide compared to placebo as maintenance therapy in keeping patients in remission over a one-year period
| Status | Completed |
| Enrollment | 92 |
| Est. completion date | September 2013 |
| Est. primary completion date | March 2013 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: 1. Signed informed consent, 2. Patients aged >= 18 years, 3. Histologically established diagnosis of collagenous colitis (CC) defined as: 1. Thickened sub-epithelial collagen layer >= 10 µm on well-orientated sections, 2. Increased amount of inflammatory cells indicating chronic inflammation in the lamina propria, 4. History of non-bloody, watery diarrhoea for more than 2 weeks prior screening in patients with newly diagnosed collagenous colitis, or history of clinical relapse for more than 1 week prior screening in patients with previously established collagenous colitis, 5. A mean of >= 3 stools/day, thereof a mean of >= 1 watery stools/day, during the week prior baseline, 6. Women of child-bearing potential and being heterosexually active have to apply appropriate contraceptive methods, e.g., hormonal contraception, intrauterine device (IUD), double-barrier method of contraception (e.g., use of a condom and spermicide), or partner has undergone vasectomy. The investigator is responsible for determining whether the subject has adequate birth control for study participation. Exclusion Criteria: 1. Other significant abnormalities at colonoscopy that may have been the cause of diarrhoea, with the exception of colonic diverticulosis and polyps < 2 cm, 2. Infectious cause of diarrhoea, 3. Untreated active celiac disease, 4. Clinical suspicion of drug-induced collagenous colitis, 5. Any severe concomitant cardiovascular, renal, endocrine, or psychiatric disorder, 6. Abnormal hepatic function (ALT or ALP > 2.5 x upper limit of normal [ULN]), liver cirrhosis, or portal hypertension, 7. Local intestinal infection, 8. Radiation therapy towards the abdominal or pelvic region, 9. Diabetes mellitus, infection, glaucoma, tuberculosis, peptic ulcer disease, or hypertension if careful medical monitoring is not ensured, 10. Known established cataract, 11. Known hereditary problems of galactose or fructose intolerance, glucose-galactose malabsorption, sucrase-isomaltase insufficiency, Lapp lactase deficiency, or congenital lactase deficiency, 12. Established osteoporosis with T-score < -2.5, 13. Pregnancy or lactation, 14. History of cancer in the last five years, 15. History of significant bowel resection, 16. Therapy with immunomodulators (azathioprine, 6-mercaptopurine, or methotrexate) in the last 3 months, 17. Treatment with oral, rectal, or intravenous corticosteroids including budesonide in the last month, 18. Known intolerance/hypersensitivity to study drug or drugs of similar chemical structure or pharmacological profile, 19. Patients who are unable to adhere to the study visit schedule and other protocol requirements according to the judgement of the investigator, 20. Participation in another clinical trial within the last 30 days, simultaneous participation in another clinical trial, or previous participation in this trial. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| Germany | Center of digestive diseases | Hamburg | |
| Sweden | University Hospital of Linköping | Linköping |
| Lead Sponsor | Collaborator |
|---|---|
| Dr. Falk Pharma GmbH | The Swedish Organization for Studies on Inflammatory Bowel Disease |
Germany, Sweden,
Münch A, Bohr J, Miehlke S, Benoni C, Olesen M, Öst Å, Strandberg L, Hellström PM, Hertervig E, Armerding P, Stehlik J, Lindberg G, Björk J, Lapidus A, Löfberg R, Bonderup O, Avnström S, Rössle M, Dilger K, Mueller R, Greinwald R, Tysk C, Ström M; BUC-63 — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Proportion of patients being in remission over 52 weeks. | Remission is defined as a mean of < 3 stools/day, thereof a mean of < 1 watery stools/day | 52 weeks | No |
| Secondary | Proportion of patients in remission at wk 4, 13, 26, and 39. | Remission is defined as a mean of < 3 stools/day, thereof a mean of < 1 watery stools/day | 39 weeks | No |
| Secondary | Adverse events (AEs) | 52 weeks | Yes |